Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Abbott Laboratories Management

Management Kriterienprüfungen 3/4

Abbott Laboratories' CEO ist Robert Ford, ernannt in Oct 2018, hat eine Amtszeit von 5.58 Jahren. Die jährliche Gesamtvergütung beträgt $23.27M, bestehend aus 6.4% Gehalt und 93.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.024% der Aktien des Unternehmens, im Wert von ARS38.66B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5 Jahre bzw. 5.3 Jahre.

Wichtige Informationen

Robert Ford

Geschäftsführender

US$23.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.4%
Amtszeit als Geschäftsführer	5.7yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	5.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Robert Ford im Vergleich zu den Einnahmen von Abbott Laboratories verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Vergütung im Vergleich zum Markt: RobertDie Gesamtvergütung ($USD23.27M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt AR ($USD6.03M).

Entschädigung vs. Einkommen: RobertDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Robert Ford (50 yo)

5.7yrs

Amtszeit

US$23,268,171

Vergütung

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Ford	Chairman of the Board	5.7yrs	US$23.27m	0.024% $ 38.2b
Philip Boudreau	CFO & Senior VP of Finance	less than a year	US$3.32m	0.0023% $ 3.6b
Hubert Allen	Executive VP	11.4yrs	US$7.42m	0.011% $ 16.9b
Robert Funck	Executive Vice President of Finance	less than a year	US$8.99m	0.016% $ 24.8b
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	9.8yrs	US$5.93m	0.0072% $ 11.5b
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.4yrs	US$5.50m	0.0035% $ 5.6b
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	keine Daten	keine Daten
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	keine Daten	keine Daten
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	keine Daten	keine Daten
Christopher Scoggins	Senior Vice President of Commercial Operations	1.4yrs	keine Daten	keine Daten
Mary Moreland	Executive Vice President of Human Resources	4.8yrs	keine Daten	0.0059% $ 9.4b
Jared Watkin	Executive Vice President of Diabetes Care	9yrs	keine Daten	0.0041% $ 6.6b

5.1yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von ABT ist erfahren und erfahren (durchschnittliche Amtszeit: 5 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Ford	Chairman of the Board	4.6yrs	US$23.27m	0.024% $ 38.2b
Daniel Starks	Independent Director	7.3yrs	US$349.29k	0.39% $ 614.2b
John Stratton	Independent Director	7.4yrs	US$341.96k	0.00020% $ 318.5m
Nancy McKinstry	Lead Independent Director	12.5yrs	US$405.96k	0.00027% $ 429.9m
Michael Roman	Independent Director	3.2yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	15.7yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	1.2yrs	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	6yrs	US$331.96k	0.00018% $ 286.6m
Sally Blount	Independent Director	12.5yrs	US$362.60k	0.00015% $ 238.9m
Claire Babineaux-Fontenot	Independent Director	1.8yrs	US$354.96k	0% $ 0
Darren McDew	Independent Director	4.8yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	2.8yrs	US$356.96k	0% $ 0

5.4yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: ABTDie Vorstandsmitglieder gelten als erfahren (5.3 Jahre durchschnittliche Amtszeit).

Abbott Laboratories Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Laboratories Announces Executive Changes

Recent updates

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q2, 2023 Results on Jul 20, 2023

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Declares Quarterly Common Cash Dividend, Payable on August 15, 2023

Abbott Receives FDA Approval for Tactiflex Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott Receives FDA Clearance for Assert-IQ™? Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

Abbott Declares Quarterly Dividend, Payable on May 15, 2023

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Proclaim™ XR

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott and Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Abbott Laboratories to Report Q4, 2022 Results on Jan 25, 2023

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Abbott Laboratories Launches the Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Abbott Increases Quarterly Dividend, Payable Feb. 15, 2023

Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home

Abbott's Freestyle Libre(R) 2 System Has Positive Impacts on Glucose Levels and Quality of Life

Abbott Laboratories to Report Q3, 2022 Results on Oct 19, 2022

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

Abbott Declares Quarterly Common Dividend, Payable November 15, 2022

Abbott Announces Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery

Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of the Securities of Abbott Laboratories

The Portnoy Law Firm Files A Class Action Lawsuit Filed on Behalf of Investors Against Abbott Laboratories

New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

U.S. Food and Drug Administration Approves Abbott's New Spinal Cord Stimulation Device and Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

Abbott Laboratories Announces Executive Changes

Abbott Laboratories Raises Earnings Guidance for 2022

Abbott Laboratories Announces Availability of 3D Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms in Canada

Abbott Receives Fda's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression

Abbott Laboratories to Report Q2, 2022 Results on Jul 20, 2022

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2022

Abbott Announces Late-Breaking Clinical Data That Demonstrate the FreeStyle Libre 3 System

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Abbott Laboratories Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

Abbott Laboratories Announces New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

Abbott Receives FDA Clearance for Its Alinity™ m STI Assay

Abbott Laboratories Announces Results from the Persist-End Study

Abbott Laboratories Launches an Upgraded Version of its Neurosphere™ Mypath™ Digital Health App

Abbott Laboratories Provides Earnings Guidance for the Year 2022

Abbott Receives Food and Drug Administration Approval for Aveir VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms

Abbott Laboratories to Report Q1, 2022 Results on Apr 20, 2022

Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit